Loading
Tempus' tumour test that reads the protein-coding part of every gene, with possible inherited findings reported from a limited list.
Tempus xE is a whole-exome panel of more than 19,000 genes sequenced from DNA, reporting potentially actionable and biologically relevant alterations and tumour mutational burden. Sequencing of a matched normal sample keeps somatic variant calls accurate, and potential germline findings may be reported from a limited set of 110 genes chosen from ACMG recommendations, NCCN guidelines and published literature; Tempus states that xE is not a validated germline panel and that these findings should not be used to diagnose hereditary cancer risk. It needs a specimen with at least 40% tumour content after macrodissection, and it can be ordered alone or in combination with Tempus xR.
DNA sequencing of the whole exome, more than 19,000 genes, from tumour tissue with a matched normal sample used to tell tumour-only changes from inherited ones.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tempus xE" OR ABSTRACT:"Tempus xE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tempus xE, not a curated reading list.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/